article · International Journal of Polymer Science
This research explored the creation of fungal chitosan nanoparticles (NFC) from *Fusarium oxysporum* and their use as carriers for bee venom (BV). The NFC had a mean diameter of 192.4 nm, with a 38.22% loading capacity and 92.42% entrapment efficiency for BV. The release of BV from the nanoparticles was pH and time-dependent, showing an initial burst followed by gradual release over 30 hours. In laboratory tests, NFC, BV, and the BV-loaded NFC nanoconjugates all exhibited dose-dependent anticancer activity against HeLa cervix carcinoma cells. The BV/NFC nanoconjugates were the most effective, inducing early apoptosis, secondary apoptosis, and secondary necrosis in the cancer cells. The study suggests that these BV-loaded fungal chitosan nanoparticles could be a potent natural antitumor agent.
This research is important because it investigates a novel approach to cancer treatment using natural compounds. By encapsulating bee venom in fungal nanoparticles, it aims to enhance its effectiveness and potentially reduce side effects, offering a promising avenue for developing new therapies against cervix carcinoma.
This early-stage research indicates a potential pathway for developing new anticancer drugs, specifically targeting cervix carcinoma. The findings suggest that bee venom-loaded fungal chitosan nanoparticles could be formulated into a therapeutic agent. Future development would involve further preclinical and clinical trials to assess efficacy and safety for pharmaceutical companies or healthcare providers.
AI-generated from the published abstract. Always read the original work before citing.
Chitosan and its nanoparticles (NPs) could be extracted from numerous fungal species and used as effectual carriers for bioactive compounds. The fungal chitosan (FC) was innovatively acquired from Fusarium oxysporum grown mycelia, characterized and used for NP synthesis and loading with bee venom (BV). The nano-FC (NFC) had 192.4 nm mean NP diameter, 38.22% loading capacity, and 92.42% entrapment efficiency. BV release from NFC was pH and time dependent; burst BV release was detected at the first 6 h, followed by gradual releases up to 30 h. The in vitro anticancer potentiality valuation, of NFC, BV, and NFC/BV nanoconjugates against HeLa cervix carcinoma, revealed that they all had potent dose-dependent anticancer activity; BV/NFC nanoconjugates were the most effective with <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mtext>I</mml:mtext><mml:msub><mml:mrow><mml:mtext>C</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>200</mml:mn><mml:mtext> </mml:mtext><mml:mi>μ</mml:mi><mml:mtext>g</mml:mtext><mml:mo>/</mml:mo><mml:mtext>mL</mml:mtext></mml:math>. The fluorescent staining of treated HeLa cells with BV/NFC nanoconjugates, with DAPI and acridine orange/propidium iodide combination, indicated the appearance of early apoptosis, secondary apoptosis, and secondary necrosis markers and their increment with exposure prolongation. The production of NFC from F. oxysporum and their loading with BV are strongly counseled for production of potent natural antitumor agent with augmented activity against cervix carcinoma.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1155/2020/2785304
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
